A Panoramic View on Gene Therapy: Applications and Complications
Abstract
Keywords
Full Text:
PDFReferences
Kaufmann, K.B., Büning, H., Galy, A., Schambach, A. and Grez, M., 2013. Gene therapy on the move. EMBO molecular medicine, 5(11), pp.1642-1661.
Wirth, T., Parker, N. and Ylä-Herttuala, S., 2013. History of gene therapy. Gene, 525(2), pp.162-169.
Gardlík, R., Pálffy, R., Hodosy, J., Lukács, J., Turna, J. and Celec, P., 2005. Vectors and delivery systems in gene therapy. Medical Science Monitor, 11(4), pp.RA110-RA121.
Wildner, O., 1999. In situ use of suicide genes for therapy of brain tumours. Annals of medicine, 31(6), pp.421-429.
Dunbar, C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K. and Sadelain, M., 2018. Gene therapy comes of age. Science, 359(6372).
van Haasteren, J., Hyde, S.C. and Gill, D.R., 2018. Lessons learned from lung and liver in-vivo gene therapy: implications for the future. Expert opinion on biological therapy, 18(9), pp.959-972.
Nayerossadat, N., Maedeh, T. and Ali, P.A., 2012. Viral and nonviral delivery systems for gene delivery. Advanced biomedical research, 1.
Gowing, G., Svendsen, S. and Svendsen, C.N., 2017. Ex vivo gene therapy for the treatment of neurological disorders. In Progress in brain research (Vol. 230, pp. 99-132). Elsevier.
Robbins, P.D. and Ghivizzani, S.C., 1998. Viral vectors for gene therapy. Pharmacology & therapeutics, 80(1), pp.35-47.
Nadeau, I. and Kamen, A., 2003. Production of adenovirus vector for gene therapy. Biotechnology advances, 20(7-8), pp.475-489.
Anson, D.S., 2004. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genetic vaccines and therapy, 2(1), pp.1-13.
Sung, Y.K. and Kim, S.W., 2019. Recent advances in the development of gene delivery systems. Biomaterials research, 23(1), pp.1-7.
Kumar, M. and Misra, A., 2011. Applications of Gene Therapy. In Challenges in Delivery of Therapeutic Genomics and Proteomics (pp. 271-323). Elsevier.
Phillips, M.I., 1999. Is gene therapy for hypertension possible?. Hypertension, 33(1), pp.8-13.
Lavu, M., Gundewar, S. and Lefer, D.J., 2011. Gene therapy for ischemic heart disease. Journal of molecular and cellular cardiology, 50(5), pp.742-750.
Pfeifer, A. and Verma, I.M., 2001. Gene therapy: promises and problems. Annual review of genomics and human genetics, 2(1), pp.177-211.
Lowenstein, P.R., Mandel, R.J., Xiong, W.D., Kroeger, K. and Castro, M.G., 2007. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Current gene therapy, 7(5), pp.347-360.
Tomanin, R. and Scarpa, M., 2004. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Current gene therapy, 4(4), pp.357-372.
Evans, J.H., 2002. Playing god?: human genetic engineering and the rationalization of public bioethical debate. University of Chicago Press.
Bostrom, N. and Roache, R., 2008. Ethical issues in human enhancement. New waves in applied ethics, pp.120-152.
Fletcher, J.C., 1983. Moral problems and ethical issues in prospective human gene therapy. Va. L. Rev., 69, p.515.
Unal, M. and Unal, D.O., 2004. Gene doping in sports. Sports Medicine, 34(6), pp.357-362.
Refbacks
Copyright (c) 2021 Annals of Pharma Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.